الفهرس Only 14 pages are availabe for public view
 |  | from | 189 |  |  |
| | | from | 189 | | |
Abstract
Central nervous system lymphoma: Rituximab and temozolomide combination has efficacy against CNS lymphomas and this immunochemotherapy combination has acceptable toxicity.
Radioimmunotherapy with yttrium-90 (90Y) ibritummomab tiuxetan or iodine-131 (131I) tositumomab. Which are murine mAbs against CD20 antigen that are conjugated to a radioactive source, they have proven efficacy for relapsed or refractory non-Hodgkin’s lymphomas.
Epratuzumab, a humanized mouse anti-CD22 mAb, has shown efficacy against indolent and aggressive non-Hodgkin’s lymphomas. Its efficacy may be improved with concomitant cytotoxic chemotherapies, such as temozolomide.
Alemtuzumab is a humanized mAb against CD52 antigen on B- and T-lymphoma cells, so used in treatment of chronic lymphocytic leukemia. And Natalizumab used to stop the trafficking of B-lymphoma cells from systemic circulation into the CNS and block the invasive behavior of primary CNS lymphomas in the brain.